Axon Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Axon Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-49,500	Closed	-$2.51M	–	13
2017 Q3	$2.51M	Buy	+49,500	New	+$2.59M	2.09%	12

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Axon Capital's IONS Position: Q4 2017 in Review

Axon Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 49,500 shares — an estimated $2.51M sold.

Axon Capital first reported a position in IONS in Q3 2017 and held it in 1 quarter. The position peaked at $2.51M in Q3 2017. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

Axon Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Axon Capital sold 49,500 Ionis Pharmaceuticals shares in Q4 2017, an estimated $2.51M.
Axon Capital first reported a position in Ionis Pharmaceuticals in Q3 2017 and held it in 1 quarter.
Axon Capital's Ionis Pharmaceuticals position peaked at $2.51M in Q3 2017.
316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on Axon Capital's 13F filing for Q4 2017, filed 14 Feb 2018.